Download Targeted knock-up of endogenous genes using a

Survey
yes no Was this document useful for you?
   Thank you for your participation!

* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project

Document related concepts

Protein moonlighting wikipedia , lookup

Gene desert wikipedia , lookup

Genome evolution wikipedia , lookup

Community fingerprinting wikipedia , lookup

Secreted frizzled-related protein 1 wikipedia , lookup

Non-coding RNA wikipedia , lookup

Transcriptional regulation wikipedia , lookup

Promoter (genetics) wikipedia , lookup

Molecular evolution wikipedia , lookup

Gene nomenclature wikipedia , lookup

Gene wikipedia , lookup

Epitranscriptome wikipedia , lookup

Two-hybrid screening wikipedia , lookup

RNA silencing wikipedia , lookup

Vectors in gene therapy wikipedia , lookup

Gene expression wikipedia , lookup

Gene expression profiling wikipedia , lookup

List of types of proteins wikipedia , lookup

Artificial gene synthesis wikipedia , lookup

Silencer (genetics) wikipedia , lookup

RNA-Seq wikipedia , lookup

Gene regulatory network wikipedia , lookup

RNA interference wikipedia , lookup

Transcript
Targeted knock-up of endogenous genes using a long non-coding RNA
chaperone to improve translation efficiency
Michael H Jones
Cell Guidance Systems, UK
Abstract
The molecular repair toolbox has been augmented in the past year by the development of a technology that can specifically
increase the amount of protein made by a targeted endogenous gene. This technology was first demonstrated in an elegant
study by Carrieri et al (Nature 491:454). This paper describes a particular lncRNA containing a SINEB2 repeat that increases
the efficiency of protein translation for a target gene to which the lncRNA specifically binds. In many ways the technique,
dubbed SINEUP, is the antithesis of RNAi. For example, the effect is achieved in trans and SINEUP can act on endogenous
genes. However, unlike RNAi, SINEUP does not interfere with mRNA levels, which remain constant. Moreover, SINEUP
currently relies on a large, 1105nt effector domain (coupled to a 73 nt gene specific binding domain) making delivery of a
therapeutic potentially more challenging than with RNAi. This exciting technology is still in its infancy and characterization
of the SINEUP system is ongoing.
Biography
Michael Jones is CEO of Cell Guidance Systems, which he founded in 2010. Prior to this, he was COO of ReproCELL and
headed Invitrogen’s corporate development team in Asia Pacific. His research career focused on cancer genomics. Michael is
the author of thirty papers and four patents.
http://www.omicsgroup.com/conferences/cell-gene-therapy-2013/